Table 1.
Characteristics of the 48 tissues analysed in the study
| Donor | Age (y) | Tissue(s) sampled | Colon segment involved | Maximum lesion diameter (mm) | Paris classification # | Pit pattern † | Microscopic appearance | Dysplasia ∆ | BRAF sequence | KRAS sequence | MLH1 staining (IHC) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumour-free | |||||||||||
| Y1 | 33 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| Y2 | 37 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| Y3 | 38 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| O1 | 71 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| O2 | 78 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| O3 | 80 | NM | CEC & SIG | – | – | – | – | – | – | – | – |
| Tumour-bearing | |||||||||||
| S1 | 88 | T+ NM | CEC | 15 | 0-IIa | IIIs | SSL | none | c.1799 T > A (V600E) | WT | positive |
| S2 | 68 | T+ NM | ASC | 12 | 0-Is | IIIs, IIIL | SSL | none | c.1799 T > A (V600E) | WT | positive |
| S3 | 61 | T+ NM | ASC | 20 | 0-IIa | II | SSL | dysplasia | c.1799 T > A (V600E) | WT | positive |
| S4 | 71 | T+ NM | ASC | 15 | 0-IIa+IIc | IV, V | SSL | dysplasia | c.1799 T > A (V600E) | WT | positive |
| S6 | 76 | T+ NM | CEC | 25 | 0-IIa | IV | SSL | dysplasia | c.1799 T > A (V600E) | WT | positive |
| S7 | 59 | T+ NM | ASC | 14 | 0-IIa | nr | SSL | dysplasia | c.1799 T > A (V600E) | WT | positive |
| S9 | 69 | T+ NM | ASC | 20 | 0-IIa | II | SSL | none | c.1799 T > A (V600E) | WT | positive |
| S10 | 45 | T+ NM | ASC | 25 | 0-Is | Is | SSL | none | c.1799 T > A (V600E) | WT | positive |
| S15 | 36 | T+ NM | ASC | 15 | 0-IIa | nr | SSL | none | c.1799 T > A (V600E) | WT | positive |
| S17 | 53 | T+ NM | CEC | 15 | 0-IIa | IIIs | SSL | none | c.1799 T > A (V600E) | WT | positive |
| A3 | 78 | T+ NM | ASC | 15 | 0-Is | IV | cADN (TA) | LGD | WT | WT | positive |
| A4 | 64 | T+ NM | ASC | 30 | 0-IIa+Is | IV | cADN (TA) | LGD | WT | c.34 G > T (G12C) | positive |
| A5 | 59 | T+ NM | ASC | 25 | 0-IIa | IIIL | cADN (TA) | LGD | WT | WT | positive |
| A6 | 73 | T+ NM | ASC | 9 | 0-Is | IIIs | cADN (TA) | LGD | WT | WT | positive |
| A7 | 64 | T+ NM | CEC | 20 | 0-Is | IIIL | cADN (TA) | LGD | WT | WT | positive |
| A9 | 73 | T+ NM | ASC | 30 | 0-IIa | IIIL | cADN (TA) | LGD | WT | c.35 G > T (G12V) | positive |
| A11 | 84 | T+ NM | ASC | 40 | 0-IIa | IIIL, IV | cADN (TA) | LGD | WT | c.35 G > T (G12V) | positive |
| A14 | 78 | T+ NM | ASC | 15 | 0-Is | IIIs | cADN (TA) | LGD | WT | WT | positive |
Abbreviations: NM, normal mucosa; T, tumour; CEC, caecum; ASC, ascending; SIG, sigmoid; cADN, conventional adenoma; TA, tubular adenoma; SSL, sessile serrated lesion; LGD, low-grade dysplasia; IHC, immunohistochemistry; nr: not reported.
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification. The Paris Endoscopic Classification of Superficial Neoplastic Lesions. Gastrointest. Endosc. 2003; 58 (suppl.): S3-S27.
† Morphological analysis of colon crypt patterns according to the Kudo classification. Kudo S et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 2001; 33: 367–73.
∆ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumours of the digestive system, editorial and consensus conference in Lyon, France, November 6–9, 1999. IARC.